Merus Labs International Inc (USA)  

(Public, NASDAQ:MSLI)   Watch this stock  
Find more results for MSLI
+0.02 (1.38%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.38 - 1.46
52 week 1.15 - 2.85
Open 1.39
Vol / Avg. 11,967.00/21,785.00
Mkt cap 147.30M
P/E     -
Div/yield     -
EPS -0.04
Shares 102.30M
Beta 1.69
Inst. own 1%
Dec 16, 2015
Q4 2015 Merus Labs International Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Merus Labs International Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2015
Merus Labs International Inc at Canaccord Genuity Growth Conference
Aug 11, 2015
Q3 2015 Merus Labs International Inc Earnings Call - Webcast
Aug 10, 2015
Q3 2015 Merus Labs International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -16.90% -30.83%
Operating margin -3.49% -15.01%
EBITD margin - 46.24%
Return on average assets -2.96% -5.65%
Return on average equity -4.84% -10.85%
Employees 6 -
CDP Score - -


100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
+1-416-5933701 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Bio & Compensation  - Reuters
Barry Fishman Chief Executive Officer, Director
Bio & Compensation  - Reuters
Andrew Patient Chief Financial Officer
Bio & Compensation  - Reuters
Robert McLay Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Frank Rotmann Vice President and Head of European Operations
Bio & Compensation  - Reuters
Robert Bloch M.D. Director
Bio & Compensation  - Reuters
Theresa Sheila Firestone Independent Director
Bio & Compensation  - Reuters
David D. Guebert CPA Independent Director
Bio & Compensation  - Reuters
Robert S. Pollock Independent Director
Bio & Compensation  - Reuters
Timothy G. Sorensen Independent Director
Bio & Compensation  - Reuters